


Author Index

- Aduma, P.J., Gupta, S.V., Stuart, A.L. and Tourigny, G., Regulatory effects of deoxyribonucleosides on the activity of 5-methoxymethyl-2'-deoxycytidine: modulation of antiherpes activity by deoxyguanosine and tetrahydrodeoxyuridine, 301
- Åkerfeldt, S., see Harmenberg, J., 193
- Åkesson-Johansson, A., see Harmenberg, J., 193
- Alin, P., see Cheetham, B.F., 27
- Baba, M., see Ito, M., 323
- Barnett, B.B., Burns, III, N.J., Park, K.J., Dawson, M.I., Kende, M. and Sidwell, R.W., Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro, 125
- Bergman, J., see Harmenberg, J., 193
- Bernstein, D.I., see Harrison, C.J., 315
- Bourke, P., see Cheetham, B.F., 27
- Brinton, M.A., see Morahan, P.S., 241
- Broen, J.J., see Cafruny, W.A., 77
- Burger, R.A., see Mead, J.R., 331
- Burger, R.A., see Morrey, J.D., 51
- Burns, III, N.J., see Barnett, B.B., 125
- Cafruny, W.A., DesJarlais, S.E., Hecht, M.L., Broen, J.J. and Jaqua, R.A., Enhancement of murine susceptibility to oral lactate dehydrogenase-elevating virus infection by non-steroidal anti-inflammatory agents, and antagonism by misoprostol, 77
- Cameron, J.M., see Coates, J.A.V., 161
- Cheetham, B.F., McInnes, B., Mantamadiotis, T., Murray, P.J., Alin, P., Bourke, P., Linnane, A.W. and Tymms, M.J., Structure-function studies of human interferons: enhanced activity on human and murine cells, 27
- Chirigos, M.A., see Morrey, J.D., 51
- Coates, J.A.V., Inggall, H.J., Pearson, B.A., Penn, C.R., Storer, R., Williamson, C. and Cameron, J.M., Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro, 161
- Coen, D.M., The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy, 287
- Coombs, J., see Mead, J.R., 331
- Cox, S., see Harmenberg, J., 193
- Dawson, M.I., see Barnett, B.B., 125
- De Clercq, E., see Ito, M., 323
- DesJarlais, S.E., see Cafruny, W.A., 77
- Devine, K.G., see McGuigan, C., 255
- Ellis, M.N., see Lobe, D.C., 87
- Endo, T., see Higuchi, H., 205
- Garcla-Villalón, D. and Gill-Fernández, C., Antiviral activity of sulfated polysaccharides against African swine fever virus, 139
- Gardner, M.B., Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents, 267
- Gessaman, A.C., see Smee, D.F., 229
- Gill-Fernández, C., see Garcla-Villalón, D., 139
- Goshima, F., see Yamada, Y., 171
- Criffin, D.E., Therapy of viral infections of the central nervous system, 1
- Gräslund, A., see Harmenberg, J., 193
- Gupta, S.V., see Aduma, P.J., 301
- Harada, H., Sakagami, H., Nagata, K., Oh-hara, T., Kawazoe, Y., Ishihama, A., Hata, N., Misawa, Y., Terada, H. and Konno, K., Possible involvement of lignin structure in anti-influenza virus activity, 41
- Harmenberg, J., Åkesson-Johansson, A., Gräslund, A., Malmfors, T., Bergman, J., Wahren, B., Åkerfeldt, S., Lundblad, L. and Cox, S., The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline, 193
- Harrison, C.J., Stanberry, L.R. and Bernstein, D.I., Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs, 315
- Hata, N., see Harada, H., 41
- Hecht, M.L., see Cafruny, W.A., 77
- Helmy, M.F., see Upadhyay, J.M., 67
- Higuchi, H., Mori, K., Kato, A., Ohkuma, T., Endo, T., Kaji, H. and Kaji, A., Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase, 205
- Hill, J.M., see Upadhyay, J.M., 67
- Hudson, J.B., Lopez-Bazzocchi, I. and Towers, G.H.N., Antiviral activities of hypericin, 101
- Huffman, J.H., see Smee, D.F., 229
- Huggins, J., see Mead, J.R., 331
- Huggins, J.W., see Smee, D.F., 229
- Ihara, T., see Ito, M., 183

- Inggall, H.J., see Coates, J.A.V., 161
 Inouye, Y., see Take, Y., 113
 Ishihama, A., see Harada, H., 41
 Ito, M., Baba, M., Shigeta, S., De Clercq, E., Walker, R.T., Tanaka, H. and Miyasaka, T., Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication *in vitro* by 1-[(2-hydroxyethoxy)methyl]-6-phenyl- thiothymine (HEPT) and recombinant alpha interferon, 323
 Ito, M., Nakano, T., Kamiya, T., Kitamura, K., Ihara, T., Kamiya, H. and Sakurai, M., Effects of tumor necrosis factor alpha on replication of varicella-zoster virus, 183
 Jaqua, R.A., see Cafruny, W.A., 77
 Jemison, M., see Upadhyay, J.M., 67
 Kaji, A., see Higuchi, H., 205
 Kaji, H., see Higuchi, H., 205
 Kamiya, H., see Ito, M., 183
 Kamiya, T., see Ito, M., 183
 Kato, A., see Higuchi, H., 205
 Kaufman, H.E., see Upadhyay, J.M., 67
 Kawazoe, Y., see Harada, H., 41
 Kende, M., see Barnett, B.B., 125
 Kende, M., see Mead, J.R., 331
 Kinchington, D., see McGuigan, C., 255
 Kitamura, K., see Ito, M., 183
 Konno, K., see Harada, H., 41
 Korba, B.E. and Milman, G., A cell culture assay for compounds which inhibit hepatitis B virus replication, 217
 Kurokawa, M., see Ochiai, H., 149
 Linnane, A.W., see Cheetham, B.F., 27
 Lobe, D.C., Spector, T. and Ellis, M.N., Synergistic topical therapy by acyclovir and A1110U for herpes simplex virus induced zosteriform rash in mice, 87
 Lopez-Bazzocchi, I., see Hudson, J.B., 101
 Lundblad, L., see Harmenberg, J., 193
 Malmfors, T., see Harmenberg, J., 193
 Mantamadiotis, T., see Cheetham, B.F., 27
 McGuigan, C., Devine, K.G., O'Connor, T.J. and Kinchington, D., Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound, 255
 McInnes, B., see Cheetham, B.F., 27
 Mead, J.R., Burger, R.A., Yonk, L.J., Coombs, J., Warren, R.P., Kende, M., Huggins, J. and Sidwell, R.W., Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice, 331
 Milman, G., see Korba, B.E., 217
 Misawa, Y., see Harada, H., 41
 Miyasaka, T., see Ito, M., 323
 Montefiori, D.C. and Zhou, J., Selective antiviral activity of synthetic soluble L-tyrosine and L-dopa melanins against human immunodeficiency virus *in vitro*, 11
 Morahan, P.S., Pinto, A., Stewart, D., Murasko, D.M. and Brinton, M.A., Varying role of alpha/beta interferon in the antiviral efficacy of synthetic immunomodulators against Semliki Forest virus infection, 241
 Mori, K., see Higuchi, H., 205
 Morrey, J.D., Warren, R.P., Okleberry, K.M., Burger, R.A., Chirigos, M.A. and Sidwell, R.W., Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection, 51
 Murasko, D.M., see Morahan, P.S., 241
 Murray, P.J., see Cheetham, B.F., 27
 Myers, M.G. and Stanberry, L.R., Drug testing for activity against varicella-zoster virus in hairless guinea pigs, 341
 Nagata, K., see Harada, H., 41
 Nakamura, S., see Take, Y., 113
 Nakano, T., see Ito, M., 183
 Nishiyama, Y., see Yamada, Y., 171
 Niwayama, S., see Ochiai, H., 149
 O'Connor, T.J., see McGuigan, C., 255
 Ochiai, H., Kurokawa, M. and Niwayama, S., Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells, 149
 Oh-hara, T., see Harada, H., 41
 Ohkuma, T., see Higuchi, H., 205
 Okleberry, K.M., see Morrey, J.D., 51
 Park, K.J., see Barnett, B.B., 125
 Pearson, B.A., see Coates, J.A.V., 161
 Penn, C.R., see Coates, J.A.V., 161
 Pinto, A., see Morahan, P.S., 241
 Sakagami, H., see Harada, H., 41
 Sakurai, M., see Ito, M., 183
 Shigeta, S., see Ito, M., 323
 Shimokata, K., see Yamada, Y., 171
 Sidwell, R.W., see Barnett, B.B., 125
 Sidwell, R.W., see Mead, J.R., 331
 Sidwell, R.W., see Morrey, J.D., 51
 Sidwell, R.W., see Smee, D.F., 229
 Smee, D.F., Huffman, J.H., Gessaman, A.C., Huggins, J.W. and Sidwell, R.W., Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice, 229

- Spector, T., see Lobe, D.C., 87
- Stanberry, L.R., see Harrison, C.J., 315
- Stanberry, L.R., see Myers, M.G., 341
- Stewart, D., see Morahan, P.S., 241
- Storer, R., see Coates, J.A.V., 161
- Stuart, A.L., see Aduma, P.J., 301
- Take, Y., Tokutake, Y., Inouye, Y., Yoshida, T., Yamamoto, A., Yamase, T. and Nakamura, S., Inhibition of proliferation of human immunodeficiency virus type 1 by novel heteropolyoxotungstates in vitro, 113
- Tanaka, H., see Ito, M., 323
- Terada, H., see Harada, H., 41
- Tokutake, Y., see Take, Y., 113
- Tourigny, G., see Aduma, P.J., 301
- Towers, G.H.N., see Hudson, J.B., 101
- Tymms, M.J., see Cheetham, B.F., 27
- Upadhyay, J.M., Hill, J.M., Jemison, M., Helmy, M.F. and Kaufman, H.E., The effect of HSV multiplication rate on antiviral drug efficacy in vitro, 67
- Wahren, B., see Harmenberg, J., 193
- Walker, R.T., see Ito, M., 323
- Warren, R.P., see Mead, J.R., 331
- Warren, R.P., see Morrey, J.D., 51
- Williamson, C., see Coates, J.A.V., 161
- Yamada, Y., Shimokata, K., Yamada, Y., Yamamoto, N., Goshima, F. and Nishiyama, Y., Inhibition of influenza A virus replication by a kanamycin derivative, 171
- Yamada, Y., see Yamada, Y., 171
- Yamamoto, A., see Take, Y., 113
- Yamamoto, N., see Yamada, Y., 171
- Yamase, T., see Take, Y., 113
- Yonk, L.J., see Mead, J.R., 331
- Yoshida, T., see Take, Y., 113
- Zhou, J., see Montefiori, D.C., 11



Subject Index

- A111OU**, Herpes simplex virus, Murine zosteriform rash model, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87
- ABMP**, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, Semliki Forest virus, Anti-interferon serum, 242
- AIDS**, Carbovir, Nucleoside, HIV, 161
- AIDS**, IFN- α , Synergistic inhibition, 323
- AIDS**, Imexon, HIV-1, Friend virus, Model, Genetically, 51
- Acquired immune deficiency syndrome**, Melanin, Antiviral therapy, 11
- Acyclovir**, Herpes simplex virus, Murine zosteriform rash model, A111OU, Synergistic topical therapy, Ribonucleotide reductase, 87
- Acyclovir**, Varicella, Antiviral testing, Animal model, Guinea pig, 6-Methoxypurine arabinoside, 341
- Aerosol treatment**, Kanamycin derivative, Influenza virus, Lysosomal pH, 171
- African swine fever virus**, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139
- Alizarin complexone**, Reverse transcriptase, Retrovirus, 205
- Ampligen**, Interferon, MVE-2, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242
- Animal model**, Varicella, Antiviral testing, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341
- Anti-AIDS**, Nucleoside analog, Nucleotide ester, Anti-HIV, Phosphoramidate, 255
- Anti-HIV**, Nucleoside analog, Nucleotide ester, Anti-AIDS, Phosphoramidate, 255
- Anti-interferon serum**, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, 242
- Antiherpes activity**, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, dNTP pool, HSV-infected cell, 301
- Antiviral therapy**, Melanin, Acquired immune deficiency syndrome, 11
- Antiviral drug**, Herpesvirus, Drug resistance, Nucleoside analog, 287
- Antiviral testing**, Varicella, Animal model, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341
- Antiviral**, HSV-1, In vitro, Stromal disease, Viral replication, 67
- Antiviral**, Immunotoxin, Gelonin, Pichinde virus, Arenavirus, Targeted delivery, 125
- Arenavirus**, Immunotoxin, Gelonin, Pichinde virus, Antiviral, Targeted delivery, 125
- Biologic response modifier**, R-837, Recurrent genital herpes, IL-2, Interferon, UV radiation, 315
- Bunyaviridae**, Punta Toro virus, Phlebovirus, Interleukin 2, Immune response, 331
- CL246,738**, Interferon, MVE-2, Ampligen, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242
- Calmodulin**, Trifluoperazine, Influenza virus, Morphogenesis, 149
- Carbovir**, Nucleoside, HIV, AIDS, 161
- Cell culture assay**, Hepatitis B virus, 217
- Deoxyguanosine potentiation**, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Antiherpes activity, dNTP pool, HSV-infected cell, 301
- Dextran sulfate**, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Heparin, 139
- dNTP pool**, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, HSV-infected cell, 301
- Drug resistance**, Antiviral drug, Herpesvirus, Nucleoside analog, 287
- Feline immunodeficiency virus**, Simian immunodeficiency virus, Lentivirus, Vaccine, 267
- Friend virus**, Imexon, AIDS, HIV-1, Model, Genetically, 51
- Fucoidan**, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Dextran sulfate, Heparin, 139
- Gelonin**, Immunotoxin, Pichinde virus, Antiviral, Arenavirus, Targeted delivery, 125
- Genetically**, Imexon, AIDS, HIV-1, Friend virus, Model, 51
- Guinea pig**, Varicella, Antiviral testing, Animal model, Acyclovir, 6-Methoxypurine arabinoside, 341

- HIV**, Carbovir, Nucleoside, AIDS, 161
- HIV-1**, Imexon, AIDS, Friend virus, Model, Genetically, 51
- HSV-1**, Antiviral, In vitro, Stromal disease, Viral replication, 67
- HSV-infected cell**, 5-Methoxymethyl-2'-deoxycytidine, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, dNTP pool, 301
- Heparin**, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, 139
- Hepatitis B virus**, Cell culture assay, 217
- Herpes simplex virus**, Murine zosteriform rash model, A1110U, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87
- Herpes simplex virus**, Indoloquinoxaline, Uncoating, 193
- Herpesvirus**, Antiviral drug, Drug resistance, Nucleoside analog, 287
- Heteropolyoxotungstate**, PM-19, Keggin structure, Human immunodeficiency virus type 1, 113
- Human immunodeficiency virus type 1**, Heteropolyoxotungstate, PM-19, Keggin structure, 113
- Hypericin**, Photosensitization, 101
- IFN- α** , AIDS, Synergistic inhibition, 323
- IL-2**, R-837, Recurrent genital herpes, Biologic response modifier, Interferon, UV radiation, 315
- Imexon**, AIDS, HIV-1, Friend virus, Model, Genetically, 51
- Immune response**, Punta Toro virus, Phlebovirus, Bunyaviridae, Interleukin 2, 331
- Immunotoxin**, Gelonin, Pichinde virus, Antiviral, Arenavirus, Targeted delivery, 125
- In vitro**, Antiviral, HSV-1, Stromal disease, Viral replication, 67
- Indoloquinoxaline**, Herpes simplex virus, Uncoating, 193
- Influenza virus**, Lignin, 41
- Influenza virus**, Trifluoperazine, Calmodulin, Morphogenesis, 149
- Influenza virus**, Kanamycin derivative, Lysosomal pH, Aerosol treatment, 171
- Interferon**, IFN, Tumor necrosis factor, TNF, Varicella-zoster virus, VZV, 183
- Interferon inducer**, Phlebovirus, Nucleoside, 229
- Interferon**, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242
- Interferon**, R-837, Recurrent genital herpes, Biologic response modifier, IL-2, UV radiation, 315
- Interleukin 2**, Punta Toro virus, Phlebovirus, Bunyaviridae, Immune response, 331
- Kanamycin derivative**, Influenza virus, Lysosomal pH, Aerosol treatment, 171
- Kappa carrageenan**, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139
- Keggin structure**, Heteropolyoxotungstate, PM-19, Human immunodeficiency virus type 1, 113
- Lambda carrageenan**, African swine fever virus, Sulfated polysaccharide, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139
- Lentivirus**, Simian immunodeficiency virus, Feline immunodeficiency virus, Vaccine, 267
- Lignin**, Influenza virus, 41
- Lysosomal pH**, Kanamycin derivative, Influenza virus, Aerosol treatment, 171
- MVE-2**, Interferon, Ampligen, CL246,738, Poly ICLC, ABMP, Semliki Forest virus, Anti-interferon serum, 242
- Melanin**, Antiviral therapy, Acquired immune deficiency syndrome, 11
- 5-Methoxymethyl-2'-deoxycytidine**, Tetrahydrodeoxyuridine (deaminase inhibitor), Deoxyguanosine potentiation, Antiherpes activity, dNTP pool, HSV-infected cell, 301
- 6-Methoxypurine arabinoside**, Varicella, Antiviral testing, Animal model, Guinea pig, Acyclovir, 341
- Misoprostol**, Virus infection, Mucosal barrier, NSAIDs, 77
- Model**, Imexon, AIDS, HIV-1, Friend virus, Genetically, 51
- Morphogenesis**, Trifluoperazine, Calmodulin, Influenza virus, 149
- Mucosal barrier**, Virus infection, Misoprostol, NSAIDs, 77
- Murine zosteriform rash model**, Herpes simplex virus, A1110U, Acyclovir, Synergistic topical therapy, Ribonucleotide reductase, 87
- NSAIDs**, Virus infection, Mucosal barrier, Misoprostol, 77
- Nucleoside**, Carbovir, HIV, AIDS, 161
- Nucleoside**, Phlebovirus, Interferon inducer, 229
- Nucleoside analog**, Nucleotide ester, Anti-HIV, Anti-AIDS, Phosphoramidate, 255
- Nucleoside analog**, Antiviral drug, Herpesvirus, Drug resistance, 287
- Nucleotide ester**, Nucleoside analog, Anti-HIV, Anti-AIDS, Phosphoramidate, 255

- PM-19**, Heteropolyoxotungstate, Keggin structure, Human immunodeficiency virus type 1, 113
- Pentosan polysulfate**, African swine fever virus, Sulfated polysaccharide, Lambda carrageenan, Kappa carrageenan, Fucoidan, Dextran sulfate, Heparin, 139
- Phlebovirus**, Nucleoside, Interferon inducer, 229
- Phlebovirus**, Punta Toro virus, Bunyaviridae, Interleukin 2, Immune response, 331
- Phosphoramidate**, Nucleoside analog, Nucleotide ester, Anti-HIV, Anti-AIDS, 255
- Photosensitization**, Hypericin, 101
- Pichinde virus**, Immunotoxin, Gelonin, Antiviral, Arenavirus, Targeted delivery, 125
- Poly ICLC**, Interferon, MVE-2, Ampligen, CL246,738, ABMP, Semliki Forest virus, Anti-interferon serum, 242
- Punta Toro virus**, Phlebovirus, Bunyaviridae, Interleukin 2, Immune response, 331
- R-837**, Recurrent genital herpes, Biologic response modifier, IL-2, Interferon, UV radiation, 315
- Recurrent genital herpes**, R-837, Biologic response modifier, IL-2, Interferon, UV radiation, 315
- Retrovirus**, Alizarin complexone, Reverse transcriptase, 205
- Reverse transcriptase**, Alizarin complexone, Retrovirus, 205
- Ribonucleotide reductase**, Herpes simplex virus, Murine zosteriform rash model, A111OU, Acyclovir, Synergistic topical therapy, 87
- Semliki Forest virus**, Interferon, MVE-2, Ampligen, CL246,738, Poly ICLC, ABMP, Anti-interferon serum, 242
- Simian immunodeficiency virus**, Feline immunodeficiency virus, Lentivirus, Vaccine, 267
- Stromal disease**, Antiviral, HSV-1, In vitro, Viral replication, 67
- Sulfated polysaccharide**, African swine fever virus, Lambda carrageenan, Kappa carrageenan, Pentosan polysulfate, Fucoidan, Dextran sulfate, Heparin, 139
- Synergistic topical therapy**, Herpes simplex virus, Murine zosteriform rash model, A111OU, Acyclovir, Ribonucleotide reductase, 87
- Synergistic inhibition**, IFN- α , AIDS, 323
- Targeted delivery**, Immunotoxin, Gelonin, Pichinde virus, Antiviral, Arenavirus, 125
- Tetrahydrodeoxyuridine (deaminase inhibitor)**, 5-Methoxymethyl-2'-deoxycytidine, Deoxyguanosine potentiation, Antiherpes activity, dNTP pool, HSV-infected cell, 301
- Trifluoperazine**, Calmodulin, Influenza virus, Morphogenesis, 149
- Tumor necrosis factor**, TNF, Varicella-zoster virus, VZV, Interferon, IFN, 183
- UV radiation**, R-837, Recurrent genital herpes, Biologic response modifier, IL-2, Interferon, 315
- Uncoating**, Herpes simplex virus, Indoloquinoline, 193
- Vaccine**, Simian immunodeficiency virus, Feline immunodeficiency virus, Lentivirus, 267
- Varicella**, Antiviral testing, Animal model, Guinea pig, Acyclovir, 6-Methoxypurine arabinoside, 341
- Varicella-zoster virus**, VZV, Tumor necrosis factor, TNF, Interferon, IFN, 183
- Viral replication**, Antiviral, HSV-1, In vitro, Stromal disease, 67
- Virus infection**, Mucosal barrier, Misoprostol, NSAIDs, 77